Results 91 to 100 of about 5,307 (166)

Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder. [PDF]

open access: yesInt J Neuropsychopharmacol
Tyler RE   +12 more
europepmc   +1 more source

Growth hormone secretagogue receptor and cannabinoid receptor type 1 intersection in the mouse brain. [PDF]

open access: yesBrain Struct Funct
Saenz C   +10 more
europepmc   +1 more source

Characterization of an 18F-Growth Hormone Secretagogue Probe for Positron Emission Tomography Imaging of the Growth Hormone Secretagogue Receptor [PDF]

open access: yes, 2017
Cardiovascular disease affects 1.6 million Canadians, of whom one-third have heart failure (HF). HF is diagnosed by imaging investigations and detection of circulating biomarkers. Most of the current imaging strategies study morphologic and gross functional changes, but fall short of imaging molecular abnormalities associated with HF.
openaire  

Ghrelin Promotes Lipid Uptake into White Adipose Tissue via Endothelial Growth Hormone Secretagogue-Receptor in Mice. [PDF]

open access: yesNutrients
Urai H   +10 more
europepmc   +1 more source

Characterization of the Growth Hormone Secretagogue Receptor in Dilated Cardiomyopathy [PDF]

open access: yes, 2019
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease of skeletal and myocardial degeneration. Eventually, dilated cardiomyopathy develops from ischemia, inflammation and fibrosis. Due to the high mortality rate, there is an emerging need to diagnose DMD cardiomyopathy at early stages. Currently, DMD cardiomyopathy is diagnosed by imaging
openaire  

Home - About - Disclaimer - Privacy